Tower Research Capital LLC TRC Has $41,000 Stock Holdings in VanEck Biotech ETF (NASDAQ:BBH)

Tower Research Capital LLC TRC lessened its position in VanEck Biotech ETF (NASDAQ:BBH) by 86.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 247 shares of the company’s stock after selling 1,625 shares during the period. Tower Research Capital LLC TRC’s holdings in VanEck Biotech ETF were worth $41,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its holdings in VanEck Biotech ETF by 1.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 28,705 shares of the company’s stock worth $4,470,000 after acquiring an additional 495 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in VanEck Biotech ETF by 3.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 14,220 shares of the company’s stock worth $2,214,000 after acquiring an additional 521 shares during the last quarter. Altfest L J & Co. Inc. grew its holdings in VanEck Biotech ETF by 3.7% during the 3rd quarter. Altfest L J & Co. Inc. now owns 7,657 shares of the company’s stock worth $1,192,000 after acquiring an additional 274 shares during the last quarter. Assetmark Inc. bought a new stake in VanEck Biotech ETF during the 3rd quarter worth about $135,000. Finally, Wealthfront Advisers LLC grew its holdings in VanEck Biotech ETF by 32.8% during the 3rd quarter. Wealthfront Advisers LLC now owns 5,229 shares of the company’s stock worth $814,000 after acquiring an additional 1,292 shares during the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Up 1.2 %

NASDAQ:BBH traded up $1.92 during mid-day trading on Thursday, reaching $160.56. 4,133 shares of the company were exchanged, compared to its average volume of 8,823. VanEck Biotech ETF has a 12 month low of $142.51 and a 12 month high of $171.04. The company has a fifty day moving average of $161.83 and a 200 day moving average of $159.77.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.